The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology

Keywords

LRRK2, Neurite, Leucine-rich repeat, Parkinsonism, Biology

References

• Calcium Influx via the NMDA Receptor Induces Immediate Early Gene Transcription by a MAP Kinase/ERK-Dependent MechanismZhengui Xia, Henryk Dudek, Cindy K. Miranti — 1996
• Neurite outgrowth in peripherin-depleted PC12 cellsCM Troy, LA Greene, ML Shelanski — 1992
• A Role for Synaptotagmin VII-Regulated Exocytosis of Lysosomes in Neurite Outgrowth from Primary Sympathetic NeuronsRosa Maria Esteves Arantes, Norma W. Andrews — 2006
• The Protein Kinase Complement of the Human GenomeGerard Manning, D B Whyte, Robert A. Martinez — 2002
• Parkinsonism genes: culprits and cluesAsa Abeliovich, M. Flint Beal — 2006
• Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity.John F. Staropoli, Caroline McDermott, Cécile Martinat — 2003
• Autosomal dominant parkinsonism associated with variable synuclein and tau pathologyZ.K. Wszolek, Ronald F. Pfeiffer, Yoshio Tsuboi — 2004
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.Alexander Zimprich, Saskia Biskup, Petra Leitner — 2004
• How MAP Kinases Are Regulated (*)Melanie H. Cobb, Elizabeth J. Goldsmith — 1995
• LIS1 RNA interference blocks neural stem cell division, morphogenesis, and motility at multiple stagesJin‐Wu Tsai, Yu Chen, Arnold R. Kriegstein — 2005
• Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.Coro Paisán-Ruı́z, Shushant Jain, E. Whitney Evans — 2004
• Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.Andrew B. West, Darren J. Moore, Saskia Biskup — 2005
• A Common Exocytotic Mechanism Mediates Axonal and Dendritic OutgrowthSonia Martı́nez-Arca, Silvia Coco, Gaëll Mainguy — 2001
• Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype.Cécile Martinat, Jean‐Jacques Bacci, Thomas Leete — 2006
• The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity.Christian Johannes Gloeckner, Norbert Kinkl, Annette Schumacher — 2006
• Mutations of the BRAF gene in human cancerHelen Davies, Graham R. Bignell, Charles Cox — 2002

Cited by

• LRRK2: an éminence grise of Wnt-mediated neurogenesis?Daniel C. Berwick, Kirsten Harvey — 2013
• [Progression of gestational hypertension to preeclampsia].Juan Fernando Romero-Arauz, Cristina Basilisa Ortiz-Díaz, Alfredo Leaños‐Miranda — 2014
• The Impact of Genetic Research on Our Understanding of Parkinson’s DiseaseIan Martin, Valina L. Dawson, Ted M. Dawson — 2010
• THE ROLE OF DOPAMINE OXIDATION IN DOPAMINE-INDUCED TOXICITY, INITIATION OF ENDOPLASMIC RETICULUM STRESS, AND POTENTIATION OF ROTENONE-INDUCED TOXICITY IN DIFFERENTIATED PC12 CELLSApril Dukes — 2007
• Investigating the Multiple Hit hypothesis of Parkinson disease using transgenic LRRK2-R1441G ratsKomal T. Shaikh — 2014
• A new rodent model of Parkinson s Disease based on neuron specific downregulation of glutathione production.M. Garrido — 2009
• The role of kalirin-7 in the pathogenesis of Parkinson disease and Huntington diseaseYu-Chun Tsai — 2012
• LRRK2 genetics and expression in the Parkinsonian brainSimone Sharma — 2010
• LRRK2 Regulates Actin Dynamics in ADP-Treated Microglia지원 변 — 2014
• LRRK2 Pathways Leading to NeurodegenerationMark Cookson — 2015
• Signal Transduction Pathways Modulated by the PD-causative Gene LRRK2Iria Carballo‐Carbajal — 2009
• Functional characterization of leucine-rich repeat kinase 2 (LRRK2) dimerizationChristian L. Klein — 2008
• Establishment and characterization of a human in vitro cell model for Parkinson 's DiseaseBenjamin Schmid — 2013
• An Early Axonopathy in a hLRRK2(R1441G) Transgenic Model of Parkinson DiseasePatricia Tagliaferro, Tatyana Kareva, Tinmarla F. Oo — 2015
• Connecting Ca2+ Stores and Parkinson DiseaseBS Kilpatrick — 2015
• Unraveling the role of defective genesMark Cookson — 2010
• Genetic mouse models of neurodegenerative diseases.Alžbeta Trančíková, David Ramonet, Darren J. Moore — 2011
• From the baker to the bedside: yeast models of Parkinson's diseaseRegina Menezes, Sandra Tenreiro, Diana Macedo — 2015
• Getting connected in the dopamine system.D VANDENHEUVEL, R. Jeroen Pasterkamp — 2008
• Intracellular signalling pathways in dopamine cell death and axonal degenerationRobert E. Burke — 2010

Related papers

• Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.Joanne Trinh, Rim Amouri, John E. Duda — 2014
• PARK8 LRRK2 parkinsonismKristoffer Haugarvoll, Zbigniew K. Wszołek — 2006
• Novel Pathogenic Lrrk2 p.Asn1437His substitution in familial Parkinson’s diseaseJan Aasly, Carles Vilariño‐Güell, Justus C. Dächsel — 2010
• Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.Michael J. Eblan, Sonja W. Scholz, Barbara Stubblefield — 2006
• Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateMargaux Morez, Antonio Jesús Lara Ordóñez, Patricia Melnyk — 2024
• LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodiesNicolas Dzamko, Amanda M. Gysbers, Rina Bandopadhyay — 2017
• Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.Anthony A. Estrada, Zachary K. Sweeney — 2015
• Comparison of gait parameters between drug-naive patients with multiple system atrophy with predominant Parkinsonism and Parkinson’s diseaseB.S. Na, Jung Min Ha, J.K. Park — 2018
• Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) DimerizationPragya Pathak, Krista K. Alexander, Leah G. Helton — 2023